Therapeutics Overview

Vitamin D and Phosphate Management Products

OPKO announced on January 8, 2013 that it has signed a definitive agreement to acquire all of the assets of Cytochroma, Inc. Cytochroma’s products, currently in Phase 3 clinical development, include a vitamin D compound, Replidea™, and a phosphate binder, Alpharen™, for use in chronic kidney disease patients.

OPKO’s proprietary point-of-care vitamin D diagnostic test currently in development will be marketed along with Replidea™.

Small Molecule and Biological Therapeutics

OPKO is currently developing several small molecule and biological therapeutics for:

• Protein up-regulation for treatment of various diseases, including cancer, heart disease, metabolic disorders, neurological disorders, and genetic disorders
• Asthma & COPD (chronic obstructive pulmonary disease)
• Parkinson’s disease
• CINV & PONV (chemotherapy-induced nausea and vomiting & post-operative nausea and vomiting)

Protein Vaccines

OPKO is also in the process of developing protein vaccines for influenza.